B-cell-Targeted therapies in relapsing forms of MS

Divyanshu Dubey, Thomas Forsthuber, Eoin P. Flanagan, Sean J. Pittock, Olaf Stüve

Research output: Contribution to journalReview articlepeer-review

8 Scopus citations


In recent years, there has been a significant increase in the therapeutic options available for the management of relapsing forms of MS. Therapies primarily targeting B cells, including therapeutic anti-CD20 monoclonal antibodies, have been evaluated in phase I, phase II, and phase III clinical trials. Results of these trials have shown their efficacy and relatively tolerable adverse effect profiles, suggesting a favorable benefit-To-risk ratio. In this review, we discuss the pathogenic role of B cells in MS and the rationale behind the utilization of B-cell depletion as a therapeutic cellular option. We also discuss the data of clinical trials for anti-CD20 antibodies in relapsing forms of MS and existing evidence for other B-cell-directed therapeutic strategies.

Original languageEnglish (US)
Article numbere405
JournalNeurology: Neuroimmunology and NeuroInflammation
Issue number6
StatePublished - Oct 23 2017

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'B-cell-Targeted therapies in relapsing forms of MS'. Together they form a unique fingerprint.

Cite this